Recent News

• 11.04.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 10.28.2025 - Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-derived CAR T-cell Therapy
• 10.26.2025 - iPSC-Derived, Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
• 10.26.2025 - Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
• 10.02.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 10.02.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 09.04.2025 - Cantor Global Healthcare Conference 2025
• 09.03.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 09.03.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 08.25.2025 - Fate Therapeutics to Present at Upcoming Investor Conferences

Recent Filings

• 10.27.2025 - 8-K Current report
• 10.27.2025 - EX-99.1 EX-99.1
• 10.21.2025 - 3 Initial statement of beneficial ownership of securities
• 10.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.20.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 10.14.2025 - EX-99.1 EX-99.1
• 10.14.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors